Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double-Pronged immune cells take aim at stubborn blood cancers

NCT ID NCT07701889

Not yet recruiting Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This phase 1 trial tests an experimental therapy called 20-19 Tan BB06z CAR-T for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to treatment. The therapy involves taking a patient's own immune T cells, genetically modifying them in a lab to recognize and attack cancer cells carrying both CD19 and CD20 proteins, and then infusing them back. The main goal is to find the safest dose and understand side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a genetically modified immune cell called 20-19 Tan BB06z CAR-T that targets both CD19 and CD20 proteins on cancer cells
What this could lead to
If successful, this could lead to a more effective CAR-T cell therapy for blood cancers that are hard to treat, potentially reducing the chance of cancer cells escaping treatment.
What could go wrong
This is an early phase 1 trial with only 21 participants, so the main goal is safety, not effectiveness. There are risks of severe side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive Burkitt lymphoma diffuse large B-cell lymphoma hematologic disorder high grade B-cell lymphoma mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC DISEASES

Contacts and locations

Locations

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.